JP5160764B2 - 特定の構造の複素環化合物を含む抗鬱剤、脳保護剤、アミロイドβ沈着抑制剤または老化抑制剤 - Google Patents
特定の構造の複素環化合物を含む抗鬱剤、脳保護剤、アミロイドβ沈着抑制剤または老化抑制剤 Download PDFInfo
- Publication number
- JP5160764B2 JP5160764B2 JP2006280768A JP2006280768A JP5160764B2 JP 5160764 B2 JP5160764 B2 JP 5160764B2 JP 2006280768 A JP2006280768 A JP 2006280768A JP 2006280768 A JP2006280768 A JP 2006280768A JP 5160764 B2 JP5160764 B2 JP 5160764B2
- Authority
- JP
- Japan
- Prior art keywords
- group
- general formula
- pyridin
- imidazo
- spiro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
- C07D513/20—Spiro-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Cardiology (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Dermatology (AREA)
- Toxicology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Compositions Of Macromolecular Compounds (AREA)
Description
後述する各実施形態に係る抗鬱剤、脳保護剤、アミロイドβ沈着抑制剤または老化抑制剤は、いずれも下記一般式(I)で示す複素環化合物を含む。
上記の複素環化合物は、一般式(I)で示されるが、この式中の各記号の定義に使用する語句の意味と例を以下に説明する。
後述する各実施形態に係る抗鬱剤、脳保護剤、アミロイドβ沈着抑制剤または老化抑制剤に含まれる複素環化合物としては、上記の特定の構造を有していればよく、特に限定するものではないが、例えば、下記に列挙する化合物を用いることができる。
後述する各実施形態に係る抗鬱剤、脳保護剤、アミロイドβ沈着抑制剤または老化抑制剤に含まれる複素環化合物は、薬学的に許容される塩として酸付加塩の形体をとってもよい。適当な酸付加塩としては、無機酸塩では例えば塩酸塩、硫酸塩、臭化水素酸塩、硝酸塩、リン酸塩等、有機酸塩では例えば酢酸塩、シュウ酸塩、プロピオン酸塩、グリコール酸塩、乳酸塩、ピルビン酸塩、マロン酸塩、コハク酸塩、マレイン酸塩、フマル酸塩、リンゴ酸塩、酒石酸塩、クエン酸塩、安息香酸塩、桂皮酸塩、メタンスルホン酸塩、ベンゼンスルホン酸塩、p−トルエンスルホン酸塩、サリチル酸塩等が挙げられる。
本実施形態に係る抗鬱剤は、既述した特定の構造(一般式(I)の構造)の複素環化合物を含む抗鬱剤である。
本実施形態に係る脳保護剤は、既述した特定の構造(一般式(I)の構造)の複素環化合物を含む脳保護剤である。
本実施形態に係るアミロイドβ沈着抑制剤は、既述した特定の構造(一般式(I)の構造)の複素環化合物を含むアミロイドβ沈着抑制剤である。
本実施形態に係る老化抑制剤は、既述した特定の構造(一般式(I)の構造)の複素環化合物を含む老化抑制剤である。
実施形態1で説明した特定の構造の複素環化合物に抗鬱作用があることを確認するために、ICR系マウス(雄)を用い、Tail suspension test(尾懸垂試験)で検討した。まず、検体を0.001、0.01及び0.1mg/kgの用量で経口投与した1時間後に、マウスの尾の先端から約1cmの部位をクリップではさみ、吊り下げた状態で6分間の観察を実施し、後半4分間の無動時間を測定した。無動時間が90秒以下になった場合を抗鬱効果有りと判定した。
実施形態2で説明した特定の構造の複素環化合物に脳保護作用があることを確認するために、化合物24の脳保護効果を、スナネズミ一過性前脳虚血モデルにおける海馬CA1領域の遅延神経細胞死軽減効果を指標として検討した。
実施形態3で説明した特定の構造の複素環化合物にアミロイドβ沈着抑制作用があることを確認するために、アミロイドβ沈着に対する化合物24の効果を検討した。
実施形態4で説明した特定の構造の複素環化合物に老化抑制作用があることを確認するために、老化促進マウス(SAM)の毛並み悪化抑制及びSAMの平均寿命の延長に対する化合物24の効果を検討した。
以下、特許文献1の実施例の方法を用いて製造した一般式(I)で示される複素環化合物の幾つかの例を示す。具体的には、国際公開第01/09131号パンフレット(特許文献1)および国際公開第2002/060907号パンフレットを参照して合成した。
下記の一般式で構造が示される、3,3−ジベンジル−8−イソプロポキシイミダゾ[1,2−a]ピリジン−2(3H)−オン(化合物1)の製造例を以下に示す。
NMR(CDCl3)δ:1.03(6H,d,J=6Hz),3.15(2H,d,J=14Hz),3.56(2H,d,J=14Hz),4.60(1H,sept.,J=6Hz),6.48(1H,t,J=7Hz),6.79(1H,d,J=8Hz),6.9−7.2(11H,m)
MS m/z:372(M+)
製造例1と同様にして、相当する出発原料から対応する一般式で構造が示される化合物2〜40をそれぞれ製造した。また、得られた化合物の各種分析結果を、対応箇所に示す。これらの分析から、得られた化合物が目的の化合物2〜40であることをそれぞれ確認した。
NMR(CDCl3)δ:3.17(2H,d,J=14Hz),3.56(2H,d,J=14Hz),3.69(3H,s),6.49(1H,t,J=7Hz),6.67(1H,d,J=8Hz),6.9−7.2(11H,m).
MS m/z:344(M+).
NMR(CDCl3)δ:0.12(2H,q,J=5Hz),0.45(2H,q,J=6Hz),0.99(1H,m),3.16(2H,d,J=14Hz),3.55(2H,d,J=14Hz),3.73(2H,d,J=7Hz),6.47(1H,t,J=7Hz),6.76(1H,d,J=8Hz),7.0−7.2(11H,m).
MS m/z:384(M+).
NMR(CDCl3)δ:3.16(2H,d,J=14Hz),3.55(2H,d,J=14Hz),6.70(1H,d,J=10Hz),7.0−7.2(12H,m).
MS m/z:348(M+).
NMR(CDCl3)δ:3.16(2H,d,J=14Hz),3.56(2H,d,J=14Hz),4.4−4.5(2H,m),5.0−5.2(2H,m),5.7−5.9(1H,m),6.47(1H,t,J=7Hz),6.74(1H,d,J=8Hz),6.9−7.2(11H,m).
MS m/z:370(M+).
NMR(CDCl3)δ:3.17(2H,d,J=14Hz),3.57(2H,d,J=14Hz),5.03(2H,s),6.39(1H,t,J=8Hz),6.65(1H,d,J=8Hz),7.0−7.2(16H,m).
MS m/z:420(M+).
NMR(CDCl3)δ:1.52(6H,d,J=7Hz),3.51(2H,q,J=7Hz),5.11(2H,s),6.14(1H,t,J=7Hz),6.41(1H,d,J=7Hz),6.63(1H,d,J=8Hz),7.0−7.2(15H,m).
MS m/z:448(M+).
NMR(CDCl3)δ:2.05(3H,s),3.31(2H,d,J=14Hz),3.56(2H,d,J=14Hz),6.60(1H,t,J=7Hz),6.9−7.2(12H,m).
MS m/z:328(M+).
・3,3−ジベンジル−5,7−ジメチルイミダゾ[1,2−a]ピリジン−2(3H)−オン(化合物9)
NMR(CDCl3)δ:2.07(3H,s),2.80(3H,s),3.40(2H,d,J=15Hz),3.71(2H,d,J=15Hz),6.11(1H,s),6.34(1H,s),7.0−7.2(10H,m).
MS m/z:342(M+).
NMR(DMSO−D6)δ:3.39(4H,s),6.60(1H,d,J=9Hz),6.8−7.2(11H,m),7.56(1H,t,J=7Hz),8.75(1H,d,J=7Hz).
MS m/z:314(M+).
NMR(CDCl3)δ:1.4−1.7(8H,m),3.15(2H,d,J=14Hz),3.55(1H,d,J=14Hz),4.7−4.9(1H,m),6.47(1H,t,J=7Hz),6.72(1H,d,J=8Hz),6.9−7.2(11H,m).
MS m/z:398(M+).
NMR(CDCl3)δ:3.17(2H,d,J=14Hz),3.55(2H,d,J=14Hz),6.9−7.3(11H,m),7.41(1H,d,J=2Hz).
MS m/z:382(M+).
NMR(CDCl3)δ:3.22(2H,d,J=14Hz),3.55(2H,d,J=14Hz),6.9−7.0(4H,m),7.1−7.4(7H,m),7.51(1H,d,J=2Hz).
MS m/z:416(M+).
NMR(CDCl3)δ:2.20(6H,s),3.14(2H,d,J=14Hz),3.48(2H,d,J=14Hz),5.05(2H,s),6.38(1H,t,J=7Hz),6.68(1H,d,J=8Hz),6.7−7.3(14H,m).
MS m/z:448(M+).
NMR(CDCl3)δ:2.01(3H,s),3.13(2H,d,J=14Hz),3.60(2H,d,J=14Hz),6.60(1H,t,J=7Hz),6.95(4H,d,J=6Hz),7.22(1H,d,J=7Hz),7.46(1H,d,J=7Hz),8.40(4H,d,J=6Hz).
MS m/z:330(M+).
NMR(CDCl3)δ:3.13(2H,d,J=14Hz),3.56(2H,d,J=14Hz),6.62(1H,t,J=7Hz),6.7−6.9(5H,m),6.9−7.1(4H,m),7.39(1H,t,J=7Hz),7.52(1H,brd,J=7Hz).
MS m/z:350(M+).
NMR(CDCl3)δ:2.86(12H,s),3.09(2H,d,J=14Hz),3.37(2H,d,J=14Hz),6.4−6.6(5H,m),6.7−6.9(5H,m),7.2−7.3(1H,m),7.37(1H,t,J=7Hz).
MS m/z:400(M+).
NMR(CDCl3)δ:3.14(2H,d,J=14Hz),3.53(2H,d,J=14Hz),6.66(1H,t,J=7Hz),6.80(1H,d,J=7Hz),6.9−7.2(8H,m),7.43(1H,t,J=7Hz),7.51(1H,brd,J=7Hz).
MS m/z:382(M+).
NMR(CDCl3)δ:3.66(6H,s),3.67(2H,d,J=15Hz),4.00(2H,d,J=15Hz),6.59(4H,d,J=9Hz),6.93(4H,d,J=9Hz),7.50(1H,1,J=7Hz),6.71(1H,d,J=7Hz),7.91(1H,t,J=7Hz),9.78(1H,d,J=7Hz).
MS m/z:374(M+).
NMR(CDCl3)δ:3.25(2H,d,J=14Hz),3.62(2H,d,J=14Hz),6.58(1H,t,J=7Hz),6.77(1H,d,J=7Hz),7.11(4H,d,J=7Hz),7.3−7.6(16H,m).
MS m/z:466(M+).
NMR(CDCl3)δ:3.19(2H,d,J=14Hz),3.70(2H,d,J=14Hz),6.6−6.8(2H,m),7.13(4H,d,J=7Hz),7.43(1H,t,J=7Hz),7.45(4H,d,J=7Hz),7.62(1H,brd,J=7Hz).
MS m/z:364(M+).
NMR(CD3OD−CDCl3(1:1))δ:3.62(2H,d,J=14Hz),3.66(2H,d,J=14Hz),6.58(4H,d,J=9Hz),6.78(4H,d,J=9Hz),7.17(1H,d,J=7Hz),7.63(1H,t,J=7Hz),8.12(1H,t,J=7Hz),9.25(1H,d,J=7Hz).
MS m/z:346(M+).
NMR(CDCl3)δ:2.56(2H,dd,J=9Hz,J=14Hz),2.86(2H,dd,J=6Hz,J=14Hz),4.99(2H,dd,J=1Hz,J=7Hz),5.04(2H,d,J=1Hz),5.4−5.6(2H,m),6.67(1H,t,J=7Hz),7.17(1H,d,J=7Hz),7.52(1H,d,J=7Hz),7.59(1H,d,J=7Hz).
MS m/z:214(M+).
NMR(CDCl3)δ:3.16(2H,d,J=16Hz),3.89(2H,d,J=16Hz),6.49(1H,t,J=7Hz),7.1−7.2(2H,m),7.2−7.3(4H,m),7.61(1H,t,J=7Hz).
MS m/z:236(M+).
NMR(CDCl3)δ:2.54(2H,dd,J=8Hz,J=14Hz),2.86(2H,dd,J=6Hz,J=14Hz),4.96(2H,dd,J=1Hz,J=5Hz),5.01(2H,d,J=1Hz),5.29(2H,s),5.4−5.6(2H,m),6.53(1H,dd,J=7Hz,J=8Hz),6.94(1H,d,J=7Hz),7.16(1H,d,J=8Hz),7.3−7.5(5H,m).
MS m/z:320(M+).
NMR(CDCl3)δ:0.9−1.1(2H,m),1.4−1.6(2H,m),1.6−1.8(2H,m),2.0−2.2(2H,m),2.3−2.5(2H,m),2.5−2.7(2H,m),6.61(1H,t,J=7Hz),7.0−7.1(4H,m),7.1−7.3(8H,m),7.58(1H,t,J=7Hz).
MS m/z:370(M+).
NMR(CDCl3):3.12(2H,d,J=17Hz),3.98(2H,d,J=17Hz),6.18(1H,t,J=7Hz),6.48(1H,d,J=7Hz),7.24(1H,d,J=7Hz),7.34(2H,d,J=7Hz),7.4−7.6(3H,m),7.86(2H,d,J=7Hz).
MS m/z:286(M+).
NMR(CDCl3)δ:3.38(2H,d,J=14Hz),3.47(2H,d,J=14Hz),6.5−6.7(3H,m),6.7−6.8(3H,m),7.2−7.5(3H,m),7.6−7.7(1H,m).
MS m/z:368(M+).
NMR(CDCl3)δ:0.7−0.9(8H,m),1.1−1.3(2H,m),1.6−1.8(2H,m),2.0−2.2(2H,m),6.73(1H,t,J=7Hz),7.19(1H,d,J=7Hz),7.50(1H,d,J=7Hz),7.63(1H,t,J=7Hz).
MS m/z:218(M+).
NMR(CDCl3)δ:3.41(2H,d,J=15Hz),3.70(2H,d,J=15Hz),6.64(1H,t,J=7Hz),6.7−7.0(5H,m),7.07(2H,dd,J=1Hz,J=5Hz),7.38(1H,d,J=7Hz),7.48(1H,t,J=7Hz).
MS m/z:326(M+).
NMR(CDCl3)δ:2.05(3H,s),3.20(2H,d,J=14Hz),3.55(2H,d,J=14Hz),6.61(1H,t,J=7Hz),6.9−7.1(4H,m),7.1−7.2(7H,m),7.78(1H,brs),8.39(1H,d,J=7Hz).
MS m/z:371(M+).
NMR(CDCl3)δ:3.37(4H,s),6.11(2H,d,J=3Hz),6.23(2H,dd,J=2Hz,J=3Hz),6.56(1H,t,J=7Hz),6.97(1H,d,J=7Hz),7.20(2H,d,J=2Hz),7.22(1H,d,J=7Hz),7.51(1H,t,J=7Hz).
MS m/z:294(M+).
NMR(CD3OD−CDCl3(1:1))δ:1.93(6H,s),7.72(1H,t,J=7Hz),7.78(1H,d,J=7Hz),8.50(1H,t,J=7Hz),9.01(1H,d,J=7Hz).
MS m/z:162(M+).
NMR(CDCl3)δ:0.6−0.9(8H,m),1.0−1.3(6H,m),1.6−1.8(2H,m),2.0−2.2(2H,m),6.71(1H,t,J=7Hz),7.19(1H,d,J=7Hz),7.50(1H,d,J=7Hz),7.62(1H,t,J=7Hz).
MS m/z:246(M+).
NMR(CDCl3)δ:2.07(2H,t,J=3Hz),2.80(2H,dd,J=3Hz,J=17Hz),3.08(2H,dd,J=2.6Hz,J=17Hz),6.75(1H,t,J=7Hz),7.24(1H,d,J=7Hz),7.69(1H,t,J=7Hz),8.02(1H,d,J=7Hz).
MS m/z:210(M+).
NMR(CDCl3)δ:3.20(2H,d,J=14Hz),3.55(2H,d,J=14Hz),6.58(1H,t,J=7Hz),6.87(1H,d,J=7Hz),6.9−7.0(4H,m),7.07(1H,d,J=7Hz),7.1−7.2(6H,m).
MS m/z:330(M+).
NMR(CDCl3)δ:3.42(2H,d,J=14Hz),3.70(2H,d,J=14Hz),4.35(2H,d,J=6Hz),6.93(1H,d,J=7Hz),7.0−7.3(16H,m),7.48(1H,d,J=7Hz),8.66(1H,brs).
MS m/z:419(M+).
NMR(CD3OD−CDCl3(1:1))δ:3.21(2H,d,J=14Hz),3.67(2H,d,J=14Hz),6.66(1H,t,J=7Hz),6.75(1H,d,J=7Hz),7.15(4H,d,J=9Hz),7.39(1H,t,J=7Hz),7.42(4H,d,J=9Hz),7.56(1H,d,J=7Hz).
MS m/z:404(M+).
NMR(CDCl3)δ:3.17(2H,d,J=14Hz),3.53(2H,d,J=14Hz),4.06(2H,brs),6.4−6.5(2H,m),6.94(1H,t,J=7Hz),7.0−7.1(4H,m),7.1−7.2(6H,m).
MS m/z:330(M+).
NMR(CDCl3)δ:3.22(2H,d,J=14Hz),3.66(2H,d,J=14Hz),3.86(6H,s),6.60(1H,t,J=7Hz),6.70(1H,d,J=7Hz),7.0−7.1(4H,m),7.35(1H,t,J=7Hz),7.50(1H,d,J=7Hz),7.8−7.9(4H,m).
MS m/z:430(M+).
下記の一般式で構造が示される、5,5−ビス(4−フルオロベンジル)イミダゾ[2,1−b]チアゾール−6(5H)−オン(化合物43)の製造例を以下に示す。
MS m/z:356(M+).
製造例3と同様にして、相当する出発原料から対応する一般式で構造が示される化合物44〜68をそれぞれ製造した。また、得られた化合物の各種分析結果を、対応箇所に示す。これらの分析から、得られた化合物が目的の化合物44〜68であることをそれぞれ確認した。
NMR(DMSO−d6)δ:3.69(2H,d,J=15Hz),3.74(2H,d,J=15Hz),7.27(1H,d,J=4Hz),7.3−7.4(4H,m),7.5−7.6(6H,m),8.44(1H,d,J=4Hz).
MS m/z:320(M+).
NMR(DMSO−d6)δ:3.42(4H,dd,J=14Hz,J=16Hz),6.9−7.0(5H,m),7.1−7.2(6H,m),8.46(1H,dd,J=3Hz,J=5Hz),9.07(1H,dd,J=2Hz,J=6Hz).
MS m/z:315(M+).
NMR(DMSO−d6)δ:2.20(6H,s),3.24(2H,d,J=14Hz),3.36(2H,d,J=14Hz),6.84(4H,d,J=8Hz),6.89(1H,d,J=4Hz),6.97(4H,d,J=8Hz),8.03(4H,d,J=4Hz).
MS m/z:348(M+).
NMR(CDCl3)δ:3.23(2H,d,J=14Hz),3.56(2H,d,J=14Hz),6.54(1H,d,J=6Hz),7.02(1H,d,J=6Hz),7.15(4H,d,J=9Hz),7.51(4H,d,J=9Hz).
MS m/z:370(M+).
NMR(CD3OD−CDCl3(1:1))δ:2.34(3H,d,J=1Hz),3.28(2H,d,J=13Hz),3.43(2H,d,J=13Hz),7.0−7.1(4H,m),7.1−7.3(7H,m).
MS m/z:334(M+).
NMR(CDCl3)δ:3.43(2H,d,J=15Hz),3.60(2H,d,J=15Hz),6.49(1H,d,J=5Hz),6.7−7.0(5H,m),7.12(2H,dd,J=1Hz,J=6Hz).
MS m/z:332(M+).
NMR(CD3OD−CDCl3(1:1))δ:3.54(2H,d,J=15Hz),3.76(2H,d,J=15Hz),6.7−6.9(5H,m),7.11(2H,dd,J=1Hz,J=5Hz),8.23(1H,dd,J=2Hz,J=6Hz),8.62(1H,dd,J=2Hz,J=4Hz).
MS m/z:327(M+).
NMR(CDCl3)δ:3.03(2H,d,J=14Hz),3.23(2H,t,J=7Hz),3.41(2H,d,J=14Hz),3.63(2H,t,J=7Hz),7.1−7.2(4H,m),7.2−7.3(6H,m).
MS m/z:322(M+).
NMR(CD3OD−CDCl3(1:1))δ:3.41(1H,d,J=15Hz),3.76(1H,d,J=15Hz),6.72(1H,t,J=7Hz),7.02(1H,d,J=9Hz),7.29(1H,d,J=9Hz),7.4−7.5(2H,m),7.58(2H,brs),7.6−7.9(4H,m).
MS m/z:274(M+).
NMR(CD3OD−CDCl3(1:1))δ:3.33(2H,d,J=16Hz),4.02(2H,d,J=16Hz),6.58(1H,t,J=7Hz),7.16(1H,d,J=7Hz),7.24(1H,d,J=9Hz),7.5−7.6(2H,m),7.74(1H,t,J=8Hz),7.8−7.9(4H,m).
MS m/z:286(M+).
NMR(CDCl3)δ:3.09(1H,dd,J=8Hz,J=15Hz),3.64(1H,dd,J=4Hz,J=15Hz),4.58(1H,dd,J=4Hz,J=8Hz),6.47(1H,t,J=7Hz),7.0−7.1(2H,m),7.1−7.2(2H,m),7.3−7.4(3H,m),7.54(1H,t,J=7Hz).
MS m/z:224(M+).
NMR(CDCl3)δ:1.55(6H,d,J=6Hz),2.51(2H,dd,J=8Hz,J=15Hz),2.76(2H,dd,J=8Hz,J=15Hz),5.1−5.3(2H,m),5.4−5.7(2H,m),6.69(1H,dd,J=5Hz,J=6Hz),7.75(1H,dd,J=2Hz,J=6Hz),8.7(1H,dd,J=2Hz,J=5Hz).
MS m/z:243(M+).
NMR(CDCl3)δ:3.24(2H,dd,J=18Hz,J=22Hz),3.88(2H,t,J=18Hz),6.55(1H,t,J=7Hz),7.01(1H,t,J=9Hz),7.10(1H,d,J=7Hz),7.2−7.3(3H,m),7.63(1H,t,J=8Hz).
MS m/z:254(M+).
NMR(CDCl3)δ:3.08(2H,dd,J=6Hz,J=17Hz),3.8−4.0(5H,m),6.49(1H,t,J=7Hz),6.8−6.9(2H,m),7.1−7.3(3H,m),7.60(1H,t,J=7Hz).
MS m/z:266(M+).
NMR(CDCl3)δ:3.14(2H,dd,J=6Hz,J=17Hz),3.82(2H,dd,J=17Hz,J=18Hz),6.57(1H,t,J=7Hz),7.08(1H,d,J=8Hz),7.1−7.3(2H,m),7.6−7.7(3H,m).
MS m/z:362(M+).
NMR(CDCl3)δ:3.26(2H,dd,J=3Hz,J=18Hz),3.93(2H,dd,J=6Hz,J=18Hz),6.56(1H,t,J=7Hz),7.15(1H,d,J=7Hz),7.23(1H,d,J=9Hz),7.44(1H,d,J=8Hz),7.6−7.7(3H,m).
MS m/z:261(M+).
NMR(CDCl3)δ:3.22(2H,d,J=17Hz),3.91(2H,d,J=17Hz),6.74(1H,d,J=7Hz),6.89(1H,d,J=7Hz),7.32(4H,s),7.6−7.7(2H,m),7.79(1H,t,J=7Hz),8.63(1H,d,J=8Hz).
MS m/z:286(M+).
NMR(CDCl3−CD3OD(1:1))δ:3.44(2H,d,J=18Hz),4.00(2H,d,J=18Hz),6.71(1H,t,J=7Hz),7.2−7.4(2H,m),7.81(1H,t,J=7Hz),7.97(2H,s).
MS m/z:294(M+).
NMR(CDCl3)δ:3.39(2H,d,J=16Hz),4.04(2H,brd,J=16Hz),6.77(1H,d,J=7Hz),6.81(1H,d,J=7Hz),7.6−7.8(2H,m),7.82(1H,brt,J=8Hz),7.95(2H,brs),8.65(1H,d,J=8Hz).
MS m/z:344(M+).
NMR(CDCl3)δ:3.17(2H,d,J=17Hz),3.92(2H,d,J=17Hz),6.53(1H,dd,J=5Hz,J=6Hz),7.44(1H,dd,J=2Hz,J=6Hz),7.32(4H,s),8.72(1H,dd,J=2Hz,J=5Hz).
MS m/z:237(M+).
NMR(CDCl3)δ:3.25(2H,d,J=17Hz),3.92(2H,d,J=17Hz),6.57(1H,t,J=7Hz),7.1−7.2(2H,m),7.44(1H,d,J=8Hz),8.5−8.7(3H,m).
MS m/z:304(M+).
NMR(CDCl3)δ:3.33(1H,d,J=17Hz),3.56(1H,d,J=17Hz),4.09(2H,t,J=17Hz),6.50(1H,t,J=7Hz),7.22(1H,d,J=9Hz),7.29(1H,d,J=7Hz),7.42(1H,d,J=8Hz),7.5−7.7(4H,m),7.83(1H,d,J=8Hz),7.92(1H,d,J=6Hz).
MS m/z:286(M+).
NMR(CDCl3)δ:2.56(2H,dd,J=9Hz,J=14Hz),2.86(2H,dd,J=6Hz,J=14Hz),4.99(2H,dd,J=1Hz,J=7Hz),5.40(2H,d,J=1Hz),5.4−5.6(2H,m),6.67(1H,t,J=7Hz),7.17(1H,d,J=7Hz),7.52(1H,d,J=7Hz),7.59(1H,d,J=7Hz).
MS m/z:214(M+).
NMR(CDCl3)δ:1.4−2.0(12H,m),2.9−3.1(2H,m),5.29(1H,brd,J=10Hz),5.8−6.0(3H,m),6.62(1H,t,J=7Hz),7.17(1H,d,J=9Hz),7.5−7.7(2H,m).
MS m/z:294(M+).
NMR(CDCl3)δ:2.62(2H,dd,J=8Hz,J=14Hz),2.89(2H,dd,J=6Hz,J=14Hz),4.9−5.1(4H,m),5.4−5.6(2H,m),6.91(1H,d,J=7Hz),7.25(1H,d,J=7Hz),7.6−7.7(2H,m),7.80(1H,t,J=8Hz),8.57(1H,d,J=8Hz).
MS m/z:264(M+).
下記の一般式で構造が示される、スピロ[イミダゾ[2,1−a]イソキノリン−2(3H)−オン−3,4’−(1’−シクロペンテン)](化合物69)の製造例を以下に示す。
NMR(CDCl3)δ:2.70(2H,d,J=17Hz),3.30(2H,d,J=17Hz),5.92(2H,s),6.89(1H,d,J=7Hz),7.33(1H,d,J=7Hz),7.6−7.8(2H,m),7.79(1H,t,J=7Hz),8.60(1H,d,J=7Hz).
MS m/z:236(M+).
製造例5と同様にして、相当する出発原料から対応する一般式で構造が示される化合物70を製造した。また、得られた化合物の各種分析結果を、対応箇所に示す。これらの分析から、得られた化合物が目的の化合物70であることを確認した。
NMR(CDCl3)δ:2.64(2H,d,J=16Hz),3.29(2H,d,J=16Hz),5.30(2H,s),5.88(2H,s),6.49(1H,dd,J=6Hz,J=8Hz),6.94(1H,dd,J=6Hz,J=8Hz),6.94(1H,d,J=8Hz),7.2−7.5(5H,m).
MS m/z:292(M+).
下記の一般式で構造が示される、3,3−ジプロピル−5,6,7,8−テトラヒドロイミダゾ[1,2−a]ピリジン−2(3H)−オン(化合物71)の製造例を以下に示す。
MS m/z:222(M+).
製造例7と同様にして、相当する出発原料から対応する一般式で構造が示される化合物72〜77をそれぞれ製造した。また、得られた化合物の各種分析結果を、対応箇所に示す。これらの分析から、得られた化合物が目的の化合物72〜77であることをそれぞれ確認した。
NMR(CDCl3)δ:0.9−1.4(8H,m),1.5−2.0(18H,m),2.79(2H,t,J=6Hz),3.30(2H,t,J=6Hz).
MS m/z:302(M+).
NMR(CDCl3)δ:0.88(6H,t,J=7Hz),0.9−1.4(8H,m),1.6−2.2(8H,m),3.2−3.4(4H,m).
MS m/z:250(M+).
NMR(CDCl3)δ:1.8−2.2(10H,m),2.3−2.5(2H,m),2.6−2.8(4H,m),6.44(1H,d,J=7Hz),7.35(1H,d,J=7Hz).
MS m/z:242(M+).
NMR(CDCl3)δ:1.8−2.3(6H,m),2.4−2.6(2H,m),6.94(1H,d,J=7Hz),7.33(1H,d,J=7Hz),7.6−7.7(2H,m),7.79(1H,t,J=6Hz),8.60(1H,d,J=8Hz).
MS m/z:238(M+).
NMR(CDCl3−CD3OD(1:1))δ:1.9−2.1(4H,m),3.0−3.2(4H,m),3.50(2H,d,J=18Hz),3.79(2H,d,J=18Hz),7.4−7.5(2H,m),7.75(2H,s),7.8−7.9(2H,m).
MS m/z:290(M+).
NMR(CDCl3−CD3OD(1:1))δ:1.9−2.1(4H,m),3.0−3.3(4H,m),3.45(2H,d,J=17Hz),3.66(2H,d,J=17Hz),7.30(4H,s).
MS m/z:240(M+).
製造例1と同様にして、相当する出発原料から対応する一般式で構造が示される化合物78〜81をそれぞれ製造した。また、得られた化合物の各種分析結果を、対応箇所に示す。これらの分析から、得られた化合物が目的の化合物78〜81であることをそれぞれ確認した。
1H−NMR(CDCl3)δ:3.11(2H, d, J=14Hz), 3.55(2H, d, J= 14Hz), 6.62(1H, t, J=7Hz), 6.78(1H, d, J=8Hz), 6.94(4H, d, J=8Hz), 7.12(4H, d, J=8Hz), 7.40(1H, t, J=7Hz), 7.47(1H, d, J=7Hz).
MS m/z: 382(M+)
1H−NMR(CDCl3)δ: 0.35−0.40 (2H, m), 0.60−0.65(2H, m), 1.30−1.40 (1H, m) 2.50−2.60(2H, m), 2.80−2.30(2H, m) , 3.94(2H, d, J=7Hz), 4.96(2H, brs), 5.02(2H, brs), 5.40−5.65(2H, m) , 6.57(1H, t, J=7Hz, J=8Hz), 6.91(1H, d, J=8Hz), 7.16(1H, d, J=7Hz)
MS m/z: 284(M+).
1H−NMR(CD3OD)δ:3.17(1H, d, J=17Hz),3.19(1H, d, J=17Hz), 3.50(1H, d, J=17Hz), 3.61(1H, d, J=17Hz), 6.63(1H, d, J=8Hz), 6.70−6.80(2H, m), 7.07(1H, d, J=8Hz), 7.12(1H, d, J=9Hz), 7.51(1H, d, J=7Hz), 7.81(1H, d, J=8Hz)
MS m/z: 352(M+).
1H−NMR(CDCl3)δ:3.22(2H, d, J=17Hz), 3.91(2H, d, J=17Hz), 6.57(1H, dd, J=6Hz, J=7Hz), 6.82(1H, d, J=6Hz), 7.27(1H, d, J=7Hz), 7.31 (4H, s)
MS m/z: 352(M+).
製造例5と同様にして、相当する出発原料から対応する一般式で構造が示される化合物82〜83をそれぞれ製造した。また、得られた化合物の各種分析結果を、対応箇所に示す。これらの分析から、得られた化合物が目的の化合物82〜83であることをそれぞれ確認した。
1H−NMR(CDCl3): 2.64(2H, d, J=17Hz), 3.29(2H, d, J=17Hz), 3.96(3H, s), 5.88(2H, s), 6.57(1H, dd, J=7Hz, J=8Hz), 6.91(1H, d, J=8Hz), 7.29(1H, d, J=7Hz)
MS m/z: 216(M+).
1H−NMR(CDCl3)δ:0.35−0.40 (2H, m), 0.60−0.70 (2H, m), 1.30−1.40(1H, m) 2.64(2H, d, J=16Hz), 3.28(2H, d, J=16Hz), 3.98(2H, d, J=7Hz), 5.88(2H, s), 6.54(1H, dd, J=7Hz, J=8Hz), 6.92(1H, d, J=8Hz), 7.28(1H, d, J=7Hz)
MS m/z: 256(M+).
Claims (16)
- 下記一般式(I)
前記一般式(I)中、下記一般式(II)で示される構造単位は、
前記R1、R2は、それぞれ独立に、水素原子、ハロゲン原子、ヒドロキシ基、アミノ基、アセチルアミノ基、ベンジルアミノ基、トリフルオロメチル基、C1−C6アルキル基、C1−C6アルコキシ基または−O−(CH2)n−R5(前記R5はビニル基、C3−C6シクロアルキル基、フェニル基、nは0または1)からなる群から選ばれる1種以上の官能基を示し、
前記R3、前記R4は、それぞれ独立に、水素原子、C1−C6アルキル基、C3−C8シクロアルキル基、−CH(R7)−R6からなる群から選ばれる1種以上の官能基を示すか、あるいは前記R3と前記R4とが結合して下記一般式(IV)に示すスピロ環を形成してもよく、
前記R7は、水素原子またはC1−C6アルキル基を示し、
前記一般式(IV)中、前記構造単位Bは、下記一般式(V)で示す複数種の構造単位から選ばれる1種以上の構造単位であり、
前記R8は、水素原子、ハロゲン原子、ヒドロキシ基、C1−C6アルコキシ基、シアノ基、トリフルオロメチル基からなる群から選ばれる1種以上の官能基を示す、
抗鬱剤。 - 請求項1記載の抗鬱剤において、
前記複素環化合物は、
3,3−ジベンジルイミダゾ[1,2−a]ピリジン−2(3H)−オン、スピロ[イミダゾ[1,2−a]ピリジン−2(3H)−オン−3,2’−インダン]、3,3−ジプロピルイミダゾ[1,2−a]ピリジン−2(3H)−オン、3,3−ジブチルイミダゾ[1,2−a]ピリジン−2(3H)−オン、5,5−ジベンジルイミダゾ[2,1−b]チアゾール−6(5H)−オン、3,3−ジベンジルイミダゾ[1,2−a]ピリミジン−2(3H)−オン、スピロ[イミダゾ[1,2−a]ピリジン−2(3H)−オン−3,2’−(4’−フルオロインダン)]、スピロ[イミダゾ[1,2−a]ピリジン−2(3H)−オン−3,2’−(5’−メトキシインダン)]、スピロ[イミダゾ[1,2−a]ピリジン−2(3H)−オン−3,2’−(4’−シアノインダン)]、スピロ[イミダゾ[2,1−a]イソキノリン−2(3H)−オン−3,2’−インダン]、スピロ[イミダゾ[1,2−a]ピリジン−2(3H)−オン−3,2’−((1,2,5−チアジアゾ)[4,5−c]インダン)]、スピロ[イミダゾ[1,2−a]ピリミジン−2(3H)−オン−3,2’−インダン]、スピロ[イミダゾ[2,1−a]イソキノリン−2(3H)−オン−3,4’−(1’−シクロペンテン)]、3,3−ビス(4−クロロベンジル)イミダゾ[1,2−a]ピリジン−2(3H)−オン、8−シクロプロピルメチルオキシ−3,3−ジアリルイミダゾ[1,2−a]ピリジン−2(3H)−オン、スピロ[イミダゾ[1,2−a]ピリジン−2(3H)−オン−3,2’−(4’−ヒドロキシインダン)]、スピロ[8−ヒドロキシ−イミダゾ[1,2−a]ピリジン−2(3H)−オン−3,2’−インダン]、スピロ[8−メトキシ−イミダゾ[1,2−a]ピリジン−2(3H)−オン−3,4’−(1’-シクロペンテン)]、スピロ[8−シクロプロピルメチルオキシイミダゾ[1,2−a]ピリジン−2(3H)−オン−3,4’−(1’-シクロペンテン)]からなる群から選ばれる1種以上の複素環化合物である、
抗鬱剤。 - 請求項1または2記載の抗鬱剤において、
経口投与型である、抗鬱剤。 - 請求項1乃至3いずれかに記載の抗鬱剤において、
哺乳動物の鬱病、躁鬱病、強迫性障害、パニック障害、不安障害からなる群から選ばれる1種以上の気分障害を抑制する機能を有する、抗鬱剤。 - 下記一般式(I)
前記一般式(I)中、下記一般式(II)で示される構造単位は、
前記R1、R2は、それぞれ独立に、水素原子、ハロゲン原子、ヒドロキシ基、アミノ基、アセチルアミノ基、ベンジルアミノ基、トリフルオロメチル基、C1−C6アルキル基、C1−C6アルコキシ基または−O−(CH2)n−R5(前記R5はビニル基、C3−C6シクロアルキル基、フェニル基、nは0または1)からなる群から選ばれる1種以上の官能基を示し、
前記R3、前記R4は、それぞれ独立に、水素原子、C1−C6アルキル基、C3−C8シクロアルキル基、−CH(R7)−R6からなる群から選ばれる1種以上の官能基を示すか、あるいは前記R3と前記R4とが結合して下記一般式(IV)に示すスピロ環を形成してもよく、
前記R7は、水素原子またはC1−C6アルキル基を示し、
前記一般式(IV)中、前記構造単位Bは、下記一般式(V)で示す複数種の構造単位から選ばれる1種以上の構造単位であり、
前記R8は、水素原子、ハロゲン原子、ヒドロキシ基、C1−C6アルコキシ基、シアノ基、トリフルオロメチル基からなる群から選ばれる1種以上の官能基を示す、
脳保護剤であって、
認知機能低下の抑制又は治療以外の用途に用いるための脳保護剤。 - 請求項5記載の脳保護剤において、
前記複素環化合物は、スピロ[イミダゾ[1,2−a]ピリジン−2(3H)−オン−3,2’−インダン]である、
脳保護剤。 - 請求項5または6記載の脳保護剤において、
経口投与型である、脳保護剤。 - 請求項5乃至7いずれかに記載の脳保護剤において、
哺乳動物の一過性脳虚血発作、脳出血、くも膜下出血、頭蓋内出血、脳梗塞、高血圧性脳症からなる群から選ばれる1種以上の脳血管障害を抑制する機能を有する、脳保護剤。 - 下記一般式(I)
前記一般式(I)中、下記一般式(II)で示される構造単位は、
前記R1、R2は、それぞれ独立に、水素原子、ハロゲン原子、ヒドロキシ基、アミノ基、アセチルアミノ基、ベンジルアミノ基、トリフルオロメチル基、C1−C6アルキル基、C1−C6アルコキシ基または−O−(CH2)n−R5(前記R5はビニル基、C3−C6シクロアルキル基、フェニル基、nは0または1)からなる群から選ばれる1種以上の官能基を示し、
前記R3、前記R4は、それぞれ独立に、水素原子、C1−C6アルキル基、C3−C8シクロアルキル基、−CH(R7)−R6からなる群から選ばれる1種以上の官能基を示すか、あるいは前記R3と前記R4とが結合して下記一般式(IV)に示すスピロ環を形成してもよく、
前記R7は、水素原子またはC1−C6アルキル基を示し、
前記一般式(IV)中、前記構造単位Bは、下記一般式(V)で示す複数種の構造単位から選ばれる1種以上の構造単位であり、
前記R8は、水素原子、ハロゲン原子、ヒドロキシ基、C1−C6アルコキシ基、シアノ基、トリフルオロメチル基からなる群から選ばれる1種以上の官能基を示す、
アミロイドβ沈着抑制剤であって、
アルツハイマー病の治療以外の用途に用いるためのアミロイドβ沈着抑制剤。 - 請求項9記載のアミロイドβ沈着抑制剤において、
前記複素環化合物は、スピロ[イミダゾ[1,2−a]ピリジン−2(3H)−オン−3,2’−インダン]である、
アミロイドβ沈着抑制剤。 - 請求項9または10記載のアミロイドβ沈着抑制剤において、
経口投与型である、アミロイドβ沈着抑制剤。 - 請求項9乃至11いずれかに記載のアミロイドβ沈着抑制剤において、
哺乳動物のアミロイドーシス、脳アミロイド血管炎、白内障、加齢黄斑変性症、リウマチ、骨粗鬆症、メタボリックシンドローム、しわ、脱毛、からなる群から選ばれる1種以上のアミロイド病理を抑制する機能を有する、アミロイドβ沈着抑制剤。 - 下記一般式(I)
前記一般式(I)中、下記一般式(II)で示される構造単位は、
前記R1、R2は、それぞれ独立に、水素原子、ハロゲン原子、ヒドロキシ基、アミノ基、アセチルアミノ基、ベンジルアミノ基、トリフルオロメチル基、C1−C6アルキル基、C1−C6アルコキシ基または−O−(CH2)n−R5(前記R5はビニル基、C3−C6シクロアルキル基、フェニル基、nは0または1)からなる群から選ばれる1種以上の官能基を示し、
前記R3、前記R4は、それぞれ独立に、水素原子、C1−C6アルキル基、C3−C8シクロアルキル基、−CH(R7)−R6からなる群から選ばれる1種以上の官能基を示すか、あるいは前記R3と前記R4とが結合して下記一般式(IV)に示すスピロ環を形成してもよく、
前記R7は、水素原子またはC1−C6アルキル基を示し、
前記一般式(IV)中、前記構造単位Bは、下記一般式(V)で示す複数種の構造単位から選ばれる1種以上の構造単位であり、
前記R8は、水素原子、ハロゲン原子、ヒドロキシ基、C1−C6アルコキシ基、シアノ基、トリフルオロメチル基からなる群から選ばれる1種以上の官能基を示す、
老化抑制剤であって、
認知機能低下の抑制又は治療以外の用途に用いるための老化抑制剤。 - 請求項13記載の老化抑制剤において、
前記複素環化合物は、スピロ[イミダゾ[1,2−a]ピリジン−2(3H)−オン−3,2’−インダン]である、
老化抑制剤。 - 請求項13または14記載の老化抑制剤において、
経口投与型である、老化抑制剤。 - 請求項13乃至15いずれかに記載の老化抑制剤において、
哺乳動物の平均寿命を延長する機能を有する、老化抑制剤。
Priority Applications (38)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2006280768A JP5160764B2 (ja) | 2006-10-13 | 2006-10-13 | 特定の構造の複素環化合物を含む抗鬱剤、脳保護剤、アミロイドβ沈着抑制剤または老化抑制剤 |
PCT/JP2007/070963 WO2008047952A2 (en) | 2006-10-13 | 2007-10-15 | Antidepressant, neuroprotectant, amyloid beta deposition inhibitor or age retardant containing heterocyclic compound |
MX2009003716A MX2009003716A (es) | 2006-10-13 | 2007-10-15 | Antidepresivo, neuroprotector, inhibidor de deposito de amiloide beta o agente de retardo del envejecimiento que contiene un compuesto heterociclico con estructura especifica. |
BRPI0719201-0A BRPI0719201A2 (pt) | 2006-10-13 | 2007-10-15 | Composição antidepressiva, neuroprotetora, inibidora de depósito de b-amilóide ou retardadora de envelhecimento, contendo composto heterocíclico com estrutura específica |
ZA200902808A ZA200902808B (en) | 2006-10-13 | 2007-10-15 | An alzheimer's disease progression inhibitor containing heterocyclic compound having specific structure |
CA2800331A CA2800331C (en) | 2006-10-13 | 2007-10-15 | Antidepressant, neuroprotectant, amyloid .beta. deposition inhibitor or age retardant containing heterocyclic compound having specific structure |
EP11006538.0A EP2388001B1 (en) | 2006-10-13 | 2007-10-15 | Age retardant containing heterocyclic compound having specific structure |
EP07830696A EP2077835A2 (en) | 2006-10-13 | 2007-10-15 | An alzheimer's disease progression inhibitor containing heterocyclic compound |
US11/872,418 US20080103158A1 (en) | 2006-10-13 | 2007-10-15 | Methods for treating delaying the progression of alzheimer's disease with heterocyclic compounds |
CN2007800381800A CN101547692B (zh) | 2006-10-13 | 2007-10-15 | 包含特殊结构杂环化合物的抗抑郁剂、神经保护剂、β-淀粉样蛋白沉积抑制剂或衰老延缓剂 |
KR1020097008993A KR101156412B1 (ko) | 2006-10-13 | 2007-10-15 | 특정 구조를 갖는 복소환 화합물을 함유하는 항우울제, 신경 보호제, 아밀로이드 β 침착 억제제 또는 노화 억제제 |
NZ576164A NZ576164A (en) | 2006-10-13 | 2007-10-15 | Antidepressant, neuroprotectant, amyloid beta deposition inhibitor or age retardant containing heterocyclic compound |
CA2800404A CA2800404C (en) | 2006-10-13 | 2007-10-15 | Antidepressant, neuroprotectant, amyloid .beta. deposition inhibitor or age retardant containing heterocyclic compound having specific structure |
EP07830697.4A EP2077836B1 (en) | 2006-10-13 | 2007-10-15 | Amyloid beta deposition inhibitor containing spiro-heterocyclic compound |
PCT/JP2007/070962 WO2008047951A2 (en) | 2006-10-13 | 2007-10-15 | An alzheimer' s disease progression inhibitor containing heterocyclic compound |
CA2666360A CA2666360C (en) | 2006-10-13 | 2007-10-15 | An alzheimer's disease progression inhibitor containing heterocyclic compound having specific structure |
CNA2007800382108A CN101547693A (zh) | 2006-10-13 | 2007-10-15 | 包含特殊结构杂环化合物的阿尔茨海默病发展抑制剂 |
TW096138439A TWI422586B (zh) | 2006-10-13 | 2007-10-15 | 一種雜環化合物用於製造使用作為抗憂鬱劑之用途 |
US11/872,408 US20080103157A1 (en) | 2006-10-13 | 2007-10-15 | Methods for treating depression, neurodegeneration, inhibiting amyloid beta deposition, delaying senescence, and extending life spans with heterocyclic compounds |
EA200970372A EA018592B1 (ru) | 2006-10-13 | 2007-10-15 | Ингибитор развития болезни альцгеймера, содержащий гетероциклическое соединение |
ZA200902809A ZA200902809B (en) | 2006-10-13 | 2007-10-15 | Antidepressant, neuroprotectant, amyloid beta deposition inhibitor or age retardant containing heterocyclic compound having specific structure |
EA200970373A EA017751B1 (ru) | 2006-10-13 | 2007-10-15 | Применение гетероциклического соединения конкретной структуры для ингибирования отложения beta-амилоида и способ ингибирования отложения beta-амилоида с использованием этого соединения |
BRPI0719781-0A2A BRPI0719781A2 (pt) | 2006-10-13 | 2007-10-15 | Inibidor da progressão do mal de alzheimer contendo composto heterocíclico |
EP11006537.2A EP2388000B1 (en) | 2006-10-13 | 2007-10-15 | Neuroprotectant containing heterocyclic compound having specific structure |
AU2007311984A AU2007311984B2 (en) | 2006-10-13 | 2007-10-15 | Antidepressant, neuroprotectant, amyloid beta deposition inhibitor or age retardant containing heterocyclic compound |
TW096138442A TWI441635B (zh) | 2006-10-13 | 2007-10-15 | 含有具特殊結構雜環化合物於抑制澱粉狀蛋白β沉澱的阿茲海默氏症發展抑制劑之用途 |
CA2800405A CA2800405C (en) | 2006-10-13 | 2007-10-15 | Antidepressant, neuroprotectant, amyloid .beta. deposition inhibitor or age retardant containing heterocyclic compound having specific structure |
NZ597949A NZ597949A (en) | 2006-10-13 | 2007-10-15 | Antidepressant, neuroprotectant, amyloid beta deposition inhibitor or age retardant containing heterocyclic compound having specific structure |
NZ576163A NZ576163A (en) | 2006-10-13 | 2007-10-15 | An alzheimer’ s disease progression inhibitor containing heterocyclic compound having specific structure |
AU2007311983A AU2007311983B2 (en) | 2006-10-13 | 2007-10-15 | An Alzheimer' s disease progression inhibitor containing heterocyclic compound |
MX2009003713A MX2009003713A (es) | 2006-10-13 | 2007-10-15 | Inhibidor de progresion de enfermedad de alzheimer que contiene un compuesto heterociclico con estructura especifica. |
KR1020097008992A KR20090086974A (ko) | 2006-10-13 | 2007-10-15 | 특정 구조를 갖는 복소환 화합물을 함유하는 알츠하이머병 진행 억제제 |
CA2666258A CA2666258C (en) | 2006-10-13 | 2007-10-15 | Antidepressant, neuroprotectant, amyloid .beta. deposition inhibitor or age retardant containing heterocyclic compound having specific structure |
EP11006539A EP2388002B1 (en) | 2006-10-13 | 2007-10-15 | Antidepressant containing heterocyclic compound having specific structure |
IL198088A IL198088A (en) | 2006-10-13 | 2009-04-07 | Heterocyclic Compounds for Life Extension, Improvement, and / or Decrease One or More Aging Symptoms |
IL198089A IL198089A0 (en) | 2006-10-13 | 2009-04-07 | An alzheimer's disease progression inhibitor containing heterocyclic compound having specific structure |
HK12104450.1A HK1164114A1 (en) | 2006-10-13 | 2010-01-13 | Antidepressant containing heterocyclic compound having specific structure |
US14/178,425 US9089561B2 (en) | 2006-10-13 | 2014-02-12 | Methods for treating depression, neurodegeneration, inhibiting amyloid β deposition, delaying senescence, and extending life spans with heterocyclic compounds |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2006280768A JP5160764B2 (ja) | 2006-10-13 | 2006-10-13 | 特定の構造の複素環化合物を含む抗鬱剤、脳保護剤、アミロイドβ沈着抑制剤または老化抑制剤 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2008094795A JP2008094795A (ja) | 2008-04-24 |
JP5160764B2 true JP5160764B2 (ja) | 2013-03-13 |
Family
ID=39069373
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2006280768A Active JP5160764B2 (ja) | 2006-10-13 | 2006-10-13 | 特定の構造の複素環化合物を含む抗鬱剤、脳保護剤、アミロイドβ沈着抑制剤または老化抑制剤 |
Country Status (16)
Country | Link |
---|---|
US (3) | US20080103158A1 (ja) |
EP (5) | EP2388002B1 (ja) |
JP (1) | JP5160764B2 (ja) |
KR (2) | KR101156412B1 (ja) |
CN (2) | CN101547693A (ja) |
AU (2) | AU2007311984B2 (ja) |
BR (2) | BRPI0719201A2 (ja) |
CA (5) | CA2666258C (ja) |
EA (2) | EA018592B1 (ja) |
HK (1) | HK1164114A1 (ja) |
IL (2) | IL198088A (ja) |
MX (2) | MX2009003716A (ja) |
NZ (3) | NZ576164A (ja) |
TW (2) | TWI422586B (ja) |
WO (2) | WO2008047952A2 (ja) |
ZA (2) | ZA200902809B (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2009143889A (ja) * | 2007-10-15 | 2009-07-02 | Zenyaku Kogyo Kk | 特定の構造の複素環化合物を含むアルツハイマー病進行抑制剤 |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4285994B2 (ja) * | 2001-01-30 | 2009-06-24 | 全薬工業株式会社 | 複素環化合物及びそれを有効成分とする脳機能改善剤 |
JP5160764B2 (ja) * | 2006-10-13 | 2013-03-13 | 全薬工業株式会社 | 特定の構造の複素環化合物を含む抗鬱剤、脳保護剤、アミロイドβ沈着抑制剤または老化抑制剤 |
US20080268067A1 (en) * | 2007-03-09 | 2008-10-30 | Llinas Rodolfo R | Methods and Compositions for Treating Thalamocortical Dysrhythmia |
US20120156134A1 (en) | 2007-12-20 | 2012-06-21 | Shayne Squires | Compositions and methods for detecting or eliminating senescent cells to diagnose or treat disease |
US20090221554A1 (en) * | 2008-02-28 | 2009-09-03 | Zenyaku Kogyo Kabushiki Kaisha | Method of treating cognitive impairment |
KR20110108355A (ko) * | 2008-12-15 | 2011-10-05 | 더 리전트 오브 더 유니버시티 오브 캘리포니아 | 새로운 단편이 형성되도록 아밀로이드 전구체 단백질의 절단을 유발하는 방법 |
WO2010115078A2 (en) * | 2009-04-02 | 2010-10-07 | Eckard Weber | Method of treating cognitive impairment |
JP2012524097A (ja) * | 2009-04-14 | 2012-10-11 | キム, ニコラス グリーン, | プロadam10セクレターゼ及び/又はベータセクレターゼレベルの減少方法 |
KR20120032479A (ko) * | 2009-05-11 | 2012-04-05 | 더 리전트 오브 더 유니버시티 오브 캘리포니아 | 유비퀴틴화된 단백질 수준을 감소시키는 방법 |
KR20140119023A (ko) | 2011-12-13 | 2014-10-08 | 버크 인스티튜트 포 리서치 온 에이징 | 의료 요법을 개선하는 방법 |
EP3231437B1 (en) | 2014-12-09 | 2020-02-05 | Nihon Sizen Hakkoh Co., Ltd. | Aging inhibitor |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US109131A (en) | 1870-11-08 | Improvement in burning hydrocarbons | ||
US2874611A (en) * | 1954-08-13 | 1959-02-24 | Luboshez Sergius N Ferris | Combined heat reflector and light transmitter structure |
US4337260A (en) * | 1981-09-10 | 1982-06-29 | Yoshitomi Pharmaceutical Industries, Ltd. | Imidazopyridine-spiro-piperidine compounds |
US5100645A (en) * | 1990-10-19 | 1992-03-31 | Royal Institution For The Advancement Of Learning (Mcgill Univ.) | Method of diagnosis of amyloidosis |
US5464843A (en) * | 1992-06-23 | 1995-11-07 | G.D. Searle & Co. | Imidazo[1,2-a]pyridinyldiacid compounds for cognitive enhancement and for treatment of cognitive disorders and neutrotoxic injury |
DE69618765T2 (de) * | 1995-02-15 | 2002-10-17 | Takeda Chemical Industries Ltd | Verwendung von kompocedinderivaten zur inhibierung der bildung oder sekretion von beta-amyloid-protein |
US20030147882A1 (en) * | 1998-05-21 | 2003-08-07 | Alan Solomon | Methods for amyloid removal using anti-amyloid antibodies |
AU766122B2 (en) * | 1999-07-30 | 2003-10-09 | Zenyaku Kogyo Kabushiki Kaisha | Azaindolizinone derivatives and cognitive enhancers comprising the same as effective components |
WO2001081960A1 (en) | 2000-04-25 | 2001-11-01 | Honeywell International Inc. | Hollow cavity light guide for the distribution of collimated light to a liquid crystal display |
JP4285994B2 (ja) * | 2001-01-30 | 2009-06-24 | 全薬工業株式会社 | 複素環化合物及びそれを有効成分とする脳機能改善剤 |
CA2461159A1 (en) * | 2001-10-22 | 2003-05-01 | Pfizer Inc. | Imidazopyridine compounds as 5-ht4 receptor modulators |
CN102584813B (zh) * | 2003-05-14 | 2016-07-06 | Ngc药物公司 | 化合物及其在调节淀粉样蛋白β中的用途 |
JP2005314348A (ja) * | 2003-05-21 | 2005-11-10 | Mitsubishi Pharma Corp | 顔面神経麻痺治療剤 |
US7521459B2 (en) * | 2003-07-28 | 2009-04-21 | Metabeauty Inc. | Method for treating damaged skin |
WO2005079780A1 (en) | 2004-01-23 | 2005-09-01 | Neurochem (International) Limited | Amidine derivatives for treating amyloidosis |
BRPI0510212A (pt) * | 2004-05-07 | 2007-10-16 | Memory Pharm Corp | 1h-indazóis, benzotiazóis, 1,2 - benzoisoxazóis, 1,2-benzoisotiazóis, e cromonas e a preparação e usos dos mesmos |
FR2874611B1 (fr) * | 2004-08-31 | 2006-11-17 | Servier Lab | Nouveaux derives d'imidazopyridine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
JP4953457B2 (ja) * | 2004-10-27 | 2012-06-13 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | プロゲステロン受容体モジュレーターとしてのピリジンイミダゾール及びアザ−インドール |
JP5160764B2 (ja) * | 2006-10-13 | 2013-03-13 | 全薬工業株式会社 | 特定の構造の複素環化合物を含む抗鬱剤、脳保護剤、アミロイドβ沈着抑制剤または老化抑制剤 |
-
2006
- 2006-10-13 JP JP2006280768A patent/JP5160764B2/ja active Active
-
2007
- 2007-10-15 BR BRPI0719201-0A patent/BRPI0719201A2/pt not_active IP Right Cessation
- 2007-10-15 US US11/872,418 patent/US20080103158A1/en not_active Abandoned
- 2007-10-15 WO PCT/JP2007/070963 patent/WO2008047952A2/en active Application Filing
- 2007-10-15 NZ NZ576164A patent/NZ576164A/en unknown
- 2007-10-15 ZA ZA200902809A patent/ZA200902809B/xx unknown
- 2007-10-15 EA EA200970372A patent/EA018592B1/ru not_active IP Right Cessation
- 2007-10-15 WO PCT/JP2007/070962 patent/WO2008047951A2/en active Application Filing
- 2007-10-15 CN CNA2007800382108A patent/CN101547693A/zh active Pending
- 2007-10-15 US US11/872,408 patent/US20080103157A1/en not_active Abandoned
- 2007-10-15 AU AU2007311984A patent/AU2007311984B2/en active Active
- 2007-10-15 ZA ZA200902808A patent/ZA200902808B/xx unknown
- 2007-10-15 NZ NZ576163A patent/NZ576163A/en not_active IP Right Cessation
- 2007-10-15 TW TW096138439A patent/TWI422586B/zh not_active IP Right Cessation
- 2007-10-15 MX MX2009003716A patent/MX2009003716A/es active IP Right Grant
- 2007-10-15 BR BRPI0719781-0A2A patent/BRPI0719781A2/pt not_active IP Right Cessation
- 2007-10-15 MX MX2009003713A patent/MX2009003713A/es active IP Right Grant
- 2007-10-15 CA CA2666258A patent/CA2666258C/en active Active
- 2007-10-15 NZ NZ597949A patent/NZ597949A/en not_active IP Right Cessation
- 2007-10-15 CA CA2800331A patent/CA2800331C/en active Active
- 2007-10-15 EA EA200970373A patent/EA017751B1/ru not_active IP Right Cessation
- 2007-10-15 EP EP11006539A patent/EP2388002B1/en active Active
- 2007-10-15 CN CN2007800381800A patent/CN101547692B/zh not_active Expired - Fee Related
- 2007-10-15 CA CA2800405A patent/CA2800405C/en active Active
- 2007-10-15 EP EP07830697.4A patent/EP2077836B1/en active Active
- 2007-10-15 EP EP11006537.2A patent/EP2388000B1/en active Active
- 2007-10-15 CA CA2800404A patent/CA2800404C/en not_active Expired - Fee Related
- 2007-10-15 CA CA2666360A patent/CA2666360C/en not_active Expired - Fee Related
- 2007-10-15 KR KR1020097008993A patent/KR101156412B1/ko not_active IP Right Cessation
- 2007-10-15 EP EP07830696A patent/EP2077835A2/en not_active Withdrawn
- 2007-10-15 AU AU2007311983A patent/AU2007311983B2/en not_active Ceased
- 2007-10-15 TW TW096138442A patent/TWI441635B/zh not_active IP Right Cessation
- 2007-10-15 EP EP11006538.0A patent/EP2388001B1/en active Active
- 2007-10-15 KR KR1020097008992A patent/KR20090086974A/ko not_active Application Discontinuation
-
2009
- 2009-04-07 IL IL198088A patent/IL198088A/en active IP Right Grant
- 2009-04-07 IL IL198089A patent/IL198089A0/en unknown
-
2010
- 2010-01-13 HK HK12104450.1A patent/HK1164114A1/xx not_active IP Right Cessation
-
2014
- 2014-02-12 US US14/178,425 patent/US9089561B2/en not_active Expired - Fee Related
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2009143889A (ja) * | 2007-10-15 | 2009-07-02 | Zenyaku Kogyo Kk | 特定の構造の複素環化合物を含むアルツハイマー病進行抑制剤 |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5160764B2 (ja) | 特定の構造の複素環化合物を含む抗鬱剤、脳保護剤、アミロイドβ沈着抑制剤または老化抑制剤 | |
TWI482773B (zh) | 氮呯并〔4,5-b〕吲哚及使用方法 | |
TW201004953A (en) | Substituted alkyl pyrimidin-4-one derivatives | |
WO2003033497A1 (en) | Tetracyclic azaindoles and -indolines having serotonin 5-ht2c activity | |
CA2858720A1 (en) | Nicotinic receptor targeted compounds and compositions | |
JP2023532888A (ja) | 細胞代謝を調節する化合物の組成及び使用方法 | |
JP5405764B2 (ja) | 特定の構造の複素環化合物を含むアルツハイマー病進行抑制剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20091006 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120710 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120910 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20121204 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20121213 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5160764 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20151221 Year of fee payment: 3 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |